Aislinn Antrim, Managing Editor

The FDA approved mitapivat, the first oral therapy for thalassemia anemia, offering hope for patients with transfusion-dependent and non–transfusion-dependent forms.

The FDA approves Accrufer for children 10 and older, offering a well-tolerated solution for iron deficiency, enhancing pediatric health outcomes.

FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.

Host Craig Beavers sits down with Marc Baines, cofounder and executive director of the HeartLife Foundation, to explore heart failure care through the lens of lived experience.

The FDA has approved a new combination therapy for BRCA2-mutated metastatic prostate cancer, showing significant efficacy in clinical trials.

As the new chair of the Advisory Committee on Immunization Practices (ACIP) signals interest in revisiting childhood and adolescent vaccine schedules, immunologist Morgan McSweeney, PhD, stresses that any changes must be anchored in decades of rigorous safety and efficacy data.

New research reveals that low cholesterol levels may indicate increased severity in Crohn disease, offering a potential new biomarker for monitoring inflammation.

New long-term data reveal avapritinib's impressive efficacy and safety in advanced systemic mastocytosis.

The Isa-VRd regimen shows consistent efficacy results across all age and frailty levels in patients with newly diagnosed multiple myeloma.

FDA approves Omisirge, the first cell therapy for severe aplastic anemia, offering hope for patients lacking donor matches and improving recovery rates.

Multidisciplinary approaches are crucial in treating complex cancer patients, focusing on tailored therapies and symptom management strategies.

Pharmacists play a crucial role in optimizing CAR-T therapy outcomes by guiding bridging therapy decisions and enhancing patient safety through proactive collaboration.

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in patients with multiple myeloma.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

Although highly efficacious, patient selection and adverse event management are crucial.

Sam Klempner, MD, discusses early findings for the bispecific T-cell engager ASP2138, including monotherapy response, combination activity, and safety enhancements through subcutaneous dosing.

The combination has the potential to redefine the standard of care for a population that previously had limited therapeutic avenues.

Diana Isaacs, PharmD, discusses evolving perceptions of obesity, the expanding role of pharmacotherapy, and how pharmacists can drive access, counseling, and long-term metabolic health.

Explore recent policy actions focused on PBM regulation, expanded pharmacy vaccine authority, and federal drug-pricing reforms.

Danny Rischin, MD, reviews findings from the C-POST trial.

Thor Halfdanarson, MD, outlines real-world challenges in radiopharmaceutical production and delivery and highlights key questions for upcoming trials, including alpha vs beta emitters and long-term toxicity.

Scott Tagawa, MD, professor of medicine and urology at Weill Cornell Medicine, discusses safety and tolerability findings observed to date, renal and hematologic considerations, and the role of pharmacists.